fda compounded semaglutide enforcement news The growing availability of GLP-1 weight-loss drugs has prompted warnings from doctors and the U.S. Food and Drug Administration. Link in comments⬇️ The availability of compounded GLP-1

What It Targets Liraglutide is designed to target: Excess weight and obesity where diet and exercise alone have not led to sufficient, sustained loss. Weightrelated metabolic markers such as elevated blood sugar, prediabetes, insulin resistance, and dyslipidemia. Cravings, portion control challenges, and emotional eating patterns that benefit from strong biological satiety support. Clients motivated to pair medication with structured nutrition, movement, and behavior change for longterm results

Overall prescribing rates (GLP-1 RA prescriptions as a proportion of all prescriptions) increased by more than one percentage point from December 2025 to March 2026 (+15.0%), representing the largest quarter-over-quarter percentage point increase observed since the start of the study period in 2019

The excellent safety profile observed in obese participants suggests that AOD-9604 is well-tolerated even in individuals with obesity-related comorbidities

Policies vary by clinic, so if you are unsure, it is acceptable to ask the provider directly